xceptor cbd pain lavender- tea salicylate cream
xceptor llc - tea salicylate 10% - topical analgesic topical pain relief for minor aches and pains.
xceptor cbd pain unscented- tea salicylate cream
xceptor llc - tea salicylate 10% - topical analgesic topical pain relief for minor aches and pains.
cellcept
roche registration gmbh - mycophenolate mofetil - graft rejection - immunosuppressants - cellcept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
cellcept
roche products (nz) ltd - mycophenolate mofetil 250mg; - capsule - 250 mg - active: mycophenolate mofetil 250mg excipient: croscarmellose sodium gelatin magnesium stearate povidone pregelatinised maize starch - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.
cellcept
roche products (nz) ltd - mycophenolate mofetil 500mg (as 542 mg of the hydrochloride salt); - powder for infusion - 500 mg - active: mycophenolate mofetil 500mg (as 542 mg of the hydrochloride salt) excipient: citric acid polysorbate 80 sodium chloride - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.
cellcept
roche products (nz) ltd - mycophenolate mofetil 200 mg/ml; - powder for oral suspension - 200 mg/ml - active: mycophenolate mofetil 200 mg/ml excipient: aspartame citric acid colloidal silicon dioxide fruit mix flavour 274869 lecithin methyl hydroxybenzoate sodium citrate dihydrate sorbitol xanthan gum - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.
cellcept
roche products (nz) ltd - mycophenolate mofetil 500mg; - tablet - 500 mg - active: mycophenolate mofetil 500mg excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry lavender y-5-10272-a povidone - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.
tyverb tablets film-coated
glaxo wellcome s.a. - lapatinib (lapatinib ditosylate monohydrate) - tablets film-coated - 250mg
tyverb tablets film-coated
glaxo wellcome s.a. - lapatinib (lapatinib ditosylate monohydrate) - tablets film-coated - 250mg
anastrozole tablet
ascend laboratories, llc - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - 1. indications and usage 1.1. adjuvant treatment anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2. first-line treatment anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3. second-line treatment anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. 4 contraindications 4.1. pregnancy and premenopausal women anastrozole tablets may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole tablets are contraindicated in women who are or may